Abstract
Background: Ischemic stroke has a poor prognosis and brings a ponderous burden on families and society. Hemorrhagic transformation (HT) after intravenous thrombolysis can increase the mortality of patients with ischemic stroke. Thus, finding new HT biomarkers to be applicable in clinical practice is of great importance.Methods: The related risk factors were recruited for analysis, including smoking, drinking, hyperlipidemia, diabetes, anamnesis, and pathological indicators. Moreover, the relationship between serum levels of caveolin-1, caveolin-2, and HT after rt-PA treatment were also studied.Results: We studied 306 patients with acute ischemic stroke treated with recombinant tissue type plasminogen activator (rt-PA) within 4.5 h of symptom onset. The results showed that Age ≥68 years, smoking, Atrial fibrillation, NIHSS score before thrombolysis ≥17, and systolic pressure 2 h after thrombolysis (mmHg) ≥149 increased the risks of HT after rt-PA administration. Remarkably, the concentration of caveolin-1 (ng/mL) ≤ 0.12 and caveolin-2 (ng/mL) ≤ 0.43 in serum increased the risks of HT after rt-PA administration.Conclusion: Knowledge on the risk factors associated with HT after rt-PA treatment may help develop treatment strategies and reduce the risk of HT. Caveolin-1 and caveolin-2 can be predictors of HT after rt-PA administration. These findings provide evidence for future further investigations aimed to validate these biomarkers.
Highlights
Ischemic stroke is a common disease with high morbidity and mortality
Between January 2014 and June 2019 306 patients with acute ischemic stroke treated with recombinant tissue type plasminogen activator (rt-PA) within 4.5 h from the affiliated Hospital of Chengde Medical College were prospectively included in this study
Three hundred and six patients with acute ischemic stroke treated with rt-PA within 4.5 h from the affiliated Hospital of Chengde Medical College were prospectively included in this study
Summary
Ischemic stroke is a common disease with high morbidity and mortality. It often has a poor prognosis and brings increasing burden on families and society [1]. Intravenous thrombolysis with recombinant tissue type plasminogen activator (rt-PA) is an effective approach to treat acute ischemic stroke. HT after intravenous thrombolysis can increase the mortality of patients with ischemic stroke [2]. The occurrent proportion of HT after acute ischemic stroke ranges from 8.5 to 30%, in which 2.1–9.4% are symptomatic HT [4,5,6]. Ischemic stroke has a poor prognosis and brings a ponderous burden on families and society. Hemorrhagic transformation (HT) after intravenous thrombolysis can increase the mortality of patients with ischemic stroke. Finding new HT biomarkers to be applicable in clinical practice is of great importance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
